Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Predicting the unpredictable real-world impact of ARV-based microbicides.

Literature DB >> 18974215

Predicting the unpredictable real-world impact of ARV-based microbicides.

Lori Heise, Sean Philpott.

Abstract

Mesh：

Substances：
Anti-HIV Agents

Year: 2008 PMID： 18974215 PMCID： PMC2597148 DOI： 10.1073/pnas.0807633105

Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN： 0027-8424 Impact factor: 11.205

× No keyword cloud information.

4 in total

1. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

Authors: D L Patton; Y T Cosgrove Sweeney; J E Balkus; L C Rohan; B J Moncla; M A Parniak; S L Hillier
Journal: Antimicrob Agents Chemother Date: 2007-03-12 Impact factor: 5.191

2. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

Authors: Vicky A Jespers; Jens M Van Roey; Greet I Beets; Anne M Buvé
Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731

3. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics.

Authors: David P Wilson; Paul M Coplan; Mark A Wainberg; Sally M Blower
Journal: Proc Natl Acad Sci U S A Date: 2008-07-07 Impact factor: 11.205

4. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Authors: Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres
Journal: AIDS Date: 2006-02-28 Impact factor: 4.177

4 in total

Predicting the unpredictable real-world impact of ARV-based microbicides.

1. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations.

2. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.

3. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics.

4. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

1. Modeling the gender-specific impact of vaginal microbicides on HIV transmission.

2. Beating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy bound.

3. Who will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries?

Review 4. Modelling the impact of antiretroviral therapy on the epidemic of HIV.